Repligen Company Leadership
| RGEN Stock | USD 152.81 2.19 1.45% |
About 75% of Repligen's corporate insiders are selling. The analysis of insiders' sentiment of trading Repligen stock suggests that many insiders are alarmed at this time. Repligen employs about 20 people. The company is managed by 20 executives with a total tenure of roughly 30 years, averaging almost 1.0 years of service per executive, having 1.0 employees per reported executive.
| Anthony Hunt CEO President CEO, Director |
| Ralf Kuriyel President Senior Vice President - Research & Development |
Insider Sentiment 25
Mostly Selling
Selling | Buying |
Latest Trades
| 2024-09-10 | Anthony Hunt | Disposed 22191 @ 145.37 | View | ||
| 2024-08-01 | Ralf Kuriyel | Disposed 4465 @ 165.67 | View | ||
| 2024-06-14 | Martin D Madaus | Acquired 1615 @ 124.94 | View | ||
| 2024-05-21 | Anthony Hunt | Disposed 20072 @ 168.26 | View |
Monitoring Repligen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Repligen |
Repligen's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Repligen's future performance. Based on our forecasts, it is anticipated that Repligen will maintain a workforce of about 100 employees by April 2025.Repligen Management Team Effectiveness
As of the 18th of March 2025, Return On Tangible Assets is likely to drop to -0.0095. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Repligen's Asset Turnover is very stable compared to the past year. Repligen's management efficiency ratios could be used to measure how well Repligen manages its routine affairs as well as how well it operates its assets and liabilities.As of the 18th of March 2025, Net Income Applicable To Common Shares is likely to grow to about 224.5 M, while Common Stock Shares Outstanding is likely to drop about 30.7 M.
Repligen Workforce Comparison
Repligen is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 186,006. Repligen adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Repligen Profit Margins
The company has Profit Margin (PM) of (0.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.69 | 0.5036 |
|
|
Repligen Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repligen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repligen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Repligen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.7273 | 8 | 11 | 62,457 | 20,125 |
| 2024-12-01 | 1.25 | 5 | 4 | 91,108 | 44,474 |
| 2024-09-01 | 0.8889 | 8 | 9 | 64,259 | 60,007 |
| 2024-06-01 | 2.4444 | 22 | 9 | 27,639 | 21,384 |
| 2024-03-01 | 0.963 | 26 | 27 | 94,399 | 46,816 |
| 2023-12-01 | 1.0 | 2 | 2 | 37,142 | 4,788 |
| 2023-09-01 | 4.0 | 4 | 1 | 30,811 | 850.00 |
| 2023-06-01 | 4.25 | 17 | 4 | 17,066 | 2,088 |
| 2023-03-01 | 1.1176 | 19 | 17 | 114,598 | 35,994 |
| 2022-12-01 | 4.0 | 4 | 1 | 50,932 | 25,000 |
| 2022-09-01 | 1.2727 | 14 | 11 | 33,358 | 53,098 |
| 2022-06-01 | 1.7778 | 16 | 9 | 25,152 | 16,809 |
| 2022-03-01 | 1.087 | 25 | 23 | 118,226 | 39,063 |
| 2021-12-01 | 0.2333 | 7 | 30 | 21,208 | 42,411 |
| 2021-09-01 | 0.2368 | 9 | 38 | 66,735 | 66,371 |
| 2021-06-01 | 0.8824 | 15 | 17 | 28,768 | 49,941 |
| 2021-03-01 | 0.2 | 11 | 55 | 33,478 | 97,842 |
| 2020-12-01 | 0.3846 | 5 | 13 | 26,847 | 52,567 |
| 2020-09-01 | 0.4444 | 4 | 9 | 54,569 | 103,797 |
| 2020-06-01 | 0.4912 | 28 | 57 | 132,763 | 240,186 |
| 2020-03-01 | 0.3864 | 17 | 44 | 97,551 | 177,901 |
| 2019-12-01 | 0.6667 | 2 | 3 | 3,957 | 4,252 |
| 2019-09-01 | 0.0833 | 1 | 12 | 20,000 | 35,989 |
| 2019-06-01 | 1.7778 | 16 | 9 | 79,405 | 60,295 |
| 2019-03-01 | 1.0909 | 12 | 11 | 109,142 | 48,437 |
| 2018-12-01 | 0.5714 | 4 | 7 | 31,753 | 65,580 |
| 2018-09-01 | 0.3333 | 5 | 15 | 16,301 | 237,568 |
| 2018-06-01 | 0.75 | 15 | 20 | 78,022 | 518,257 |
| 2018-03-01 | 1.2 | 12 | 10 | 620,835 | 49,657 |
| 2017-12-01 | 0.6 | 3 | 5 | 12,729 | 925,458 |
| 2017-06-01 | 12.0 | 12 | 1 | 23,373 | 2,275 |
| 2017-03-01 | 1.0667 | 16 | 15 | 303,765 | 74,292 |
| 2016-09-01 | 0.5 | 1 | 2 | 20,000 | 3,024 |
| 2016-06-01 | 2.125 | 17 | 8 | 68,062 | 51,493 |
| 2016-03-01 | 2.0 | 10 | 5 | 178,940 | 6,484 |
| 2015-12-01 | 3.0 | 3 | 1 | 7,000 | 5,000 |
| 2015-09-01 | 1.0 | 1 | 1 | 24,000 | 325.00 |
| 2015-06-01 | 1.4 | 14 | 10 | 26,388 | 232,625 |
| 2015-03-01 | 1.25 | 10 | 8 | 119,519 | 128,483 |
| 2014-12-01 | 0.625 | 5 | 8 | 62,000 | 126,158 |
| 2014-09-01 | 1.0 | 3 | 3 | 20,000 | 45,000 |
| 2014-06-01 | 0.9459 | 35 | 37 | 514,181 | 589,312 |
| 2014-03-01 | 10.0 | 10 | 1 | 142,524 | 40,000 |
| 2013-09-01 | 0.3333 | 1 | 3 | 50,000 | 109,858 |
| 2013-06-01 | 0.5455 | 18 | 33 | 310,016 | 504,087 |
| 2013-03-01 | 1.2857 | 9 | 7 | 385,000 | 179,973 |
| 2012-09-01 | 0.3333 | 8 | 24 | 102,000 | 400,000 |
| 2012-03-01 | 0.3846 | 5 | 13 | 160,000 | 341,551 |
| 2011-09-01 | 2.0 | 2 | 1 | 31,000 | 25,000 |
| 2011-03-01 | 0.25 | 1 | 4 | 5,000 | 85,000 |
| 2009-09-01 | 1.25 | 5 | 4 | 104,000 | 451,800 |
| 2008-09-01 | 3.0 | 6 | 2 | 109,000 | 10,000 |
| 2008-03-01 | 0.1304 | 3 | 23 | 115,000 | 76,368 |
| 2007-12-01 | 0.5556 | 10 | 18 | 155,400 | 92,600 |
| 2007-09-01 | 3.5 | 7 | 2 | 860,000 | 139,465 |
| 2007-06-01 | 1.2857 | 9 | 7 | 127,000 | 89,444 |
| 2007-03-01 | 0.3571 | 5 | 14 | 160,000 | 78,000 |
| 2006-09-01 | 2.2 | 11 | 5 | 108,000 | 65,000 |
| 2006-03-01 | 0.8333 | 15 | 18 | 596,500 | 236,400 |
| 2005-12-01 | 2.0 | 6 | 3 | 17,000 | 36,576 |
| 2005-09-01 | 0.4615 | 6 | 13 | 85,000 | 60,425 |
| 2005-06-01 | 6.0 | 6 | 1 | 175,000 | 15,000 |
| 2005-03-01 | 2.5 | 5 | 2 | 45,000 | 20,000 |
| 2004-09-01 | 6.0 | 6 | 1 | 85,000 | 24,000 |
| 2004-06-01 | 1.75 | 7 | 4 | 220,000 | 25,000 |
| 2004-03-01 | 0.5 | 1 | 2 | 5,000 | 5,000 |
| 2003-12-01 | 1.25 | 20 | 16 | 140,000 | 128,000 |
Repligen Notable Stakeholders
A Repligen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Repligen often face trade-offs trying to please all of them. Repligen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Repligen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anthony Hunt | President CEO, Director | Profile | |
| Olivier Loeillot | President Officer | Profile | |
| Ralf Kuriyel | Senior Vice President - Research & Development | Profile | |
| Mark Salerno | VP Analytics | Profile | |
| Christine Gebski | Senior Chromatography | Profile | |
| Kimberly Cornwell | General Counsel | Profile | |
| Dianne Heiler | Senior Sustainability | Profile | |
| James Bylund | Chief Officer | Profile | |
| Kola Otitoju | Senior Development | Profile | |
| Stephen Tingley | VP Sales | Profile | |
| Jaime Humara | Senior Marketing | Profile | |
| Jon Snodgres | Chief Officer | Profile | |
| Rachel Goodrich | VP Marketing | Profile | |
| Neil Whitfield | Vice Sales | Profile | |
| Leslie Galvin | Global Resources | Profile | |
| Keith Robinson | Chief Officer | Profile | |
| Sondra Newman | Global Relations | Profile | |
| Jason Garland | Chief Officer | Profile | |
| Teresa Ferragamo | Senior Marketing | Profile | |
| Craig Harrison | VP Analytics | Profile |
About Repligen Management Performance
The success or failure of an entity such as Repligen often depends on how effective the management is. Repligen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Repligen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Repligen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
Repligen Workforce Analysis
Traditionally, organizations such as Repligen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Repligen within its industry.Repligen Manpower Efficiency
Return on Repligen Manpower
| Revenue Per Employee | 31.7M | |
| Revenue Per Executive | 31.7M | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 1.3M | |
| Working Capital Per Employee | 47.6M | |
| Working Capital Per Executive | 47.6M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Earnings Share (0.47) | Revenue Per Share | Quarterly Revenue Growth 0.006 | Return On Assets |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.